BRPI0418283A - formulação de liberação prolongada e processo para a preparação de uma formulação de liberação prolongada - Google Patents

formulação de liberação prolongada e processo para a preparação de uma formulação de liberação prolongada

Info

Publication number
BRPI0418283A
BRPI0418283A BRPI0418283-9A BRPI0418283A BRPI0418283A BR PI0418283 A BRPI0418283 A BR PI0418283A BR PI0418283 A BRPI0418283 A BR PI0418283A BR PI0418283 A BRPI0418283 A BR PI0418283A
Authority
BR
Brazil
Prior art keywords
release formulation
extended release
preparing
formulation
extended
Prior art date
Application number
BRPI0418283-9A
Other languages
English (en)
Inventor
Sampad Bhattacharya
Rajesh Kshirsagar
Mayank Joshi
Sandeep Pandita
Original Assignee
Alembic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Ltd filed Critical Alembic Ltd
Publication of BRPI0418283A publication Critical patent/BRPI0418283A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

FORMULAçãO DE LIBERAçãO PROLONGADA E PROCESSO PARA A PREPARAçãO DE UMA FORMULAçãO DE LIBERAçãO PROLONGADA A presente invenção refere-se a uma formulação farmacêutica de liberação prolongada para uma única ministração diária compreendido hidrocloreto de venlafaxina e excipientes farmaceuticamente aceitáveis. Mais particulamente, a presente invenção refere-se a uma composição de liberação prolongada na forma de mini comprimidos os quais são incorporados em uma cápsula de gelatina dura.
BRPI0418283-9A 2004-02-04 2004-10-27 formulação de liberação prolongada e processo para a preparação de uma formulação de liberação prolongada BRPI0418283A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN117MU2004 2004-02-04
IN980MU2004 2004-09-13
PCT/IN2004/000340 WO2005074895A1 (en) 2004-02-04 2004-10-27 Extended release coated microtablets of venlafaxine hydrochloride

Publications (1)

Publication Number Publication Date
BRPI0418283A true BRPI0418283A (pt) 2007-05-02

Family

ID=34809925

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418283-9A BRPI0418283A (pt) 2004-02-04 2004-10-27 formulação de liberação prolongada e processo para a preparação de uma formulação de liberação prolongada

Country Status (23)

Country Link
US (1) US7807195B2 (pt)
EP (1) EP1711169B1 (pt)
JP (1) JP2007520547A (pt)
KR (1) KR20070000439A (pt)
AT (1) ATE361743T1 (pt)
AU (1) AU2004315136B2 (pt)
BR (1) BRPI0418283A (pt)
CA (1) CA2555295C (pt)
CY (1) CY1106741T1 (pt)
DE (1) DE602004006443T2 (pt)
DK (1) DK1711169T3 (pt)
ES (1) ES2287813T3 (pt)
HR (1) HRP20070353T3 (pt)
IL (1) IL177243A0 (pt)
MX (1) MXPA06008854A (pt)
NO (1) NO20063809L (pt)
NZ (1) NZ548504A (pt)
PL (1) PL1711169T3 (pt)
PT (1) PT1711169E (pt)
RU (1) RU2340331C2 (pt)
SI (1) SI1711169T1 (pt)
UA (1) UA82597C2 (pt)
WO (1) WO2005074895A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2004047718A2 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
WO2006136927A1 (en) * 2005-06-22 2006-12-28 Glenmark Pharmaceuticals Limited Extended release formulations comprising venlafaxine
WO2007016315A2 (en) * 2005-07-28 2007-02-08 Dr. Reddy's Laboratories Ltd. Extended release venlafaxine compositions
US20090175934A1 (en) * 2006-03-08 2009-07-09 Jubilant Organosys Ltd. Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
WO2007112574A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
WO2008074145A1 (en) * 2006-12-20 2008-06-26 Genpharm Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
EP2124963A4 (en) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc COMPOSITION WITH A BISPHOSPHONIC ACID IN COMBINATION WITH VITAMIN D
TWI391150B (zh) * 2008-01-22 2013-04-01 Taiwan Biotech Co Ltd 腸溶性長效塗覆芯與藥物劑型及其製造方法
CN101756934A (zh) * 2008-12-10 2010-06-30 上海复星普适医药科技有限公司 文拉法辛缓释制剂的制备方法
KR101787481B1 (ko) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐
US9789093B2 (en) 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
BR112018011948B1 (pt) * 2015-12-25 2023-10-03 Fujifilm Toyama Chemical Co., Ltd Comprimido compreendendo 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil) azetidin-3-ol ou sal do mesmo
KR102062052B1 (ko) * 2018-03-20 2020-01-03 일양약품주식회사 베타네콜 서방성 제제 및 이의 제조방법
KR20230067863A (ko) 2021-11-10 2023-05-17 박찬호 스마트 계량도구 및 이를 이용한 요리보조 시스템

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
ATE271864T1 (de) * 1998-05-15 2004-08-15 Warner Lambert Co Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
WO2001037815A1 (en) 1999-11-22 2001-05-31 Alza Corporation Osmotic dosage form comprising first and second
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
EP1385486A4 (en) * 2001-04-18 2006-05-17 Nostrum Pharmaceuticals Inc NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
AU2002358270A1 (en) 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US6696496B2 (en) * 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
BR0312445A (pt) * 2002-06-07 2005-05-10 Ranbaxy Lab Ltd Sistemas multiunitários para disponibilização de fármaco de liberação modificada
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7058999B2 (en) * 2002-10-24 2006-06-13 Paramount Bed Co., Ltd. Electric bed and control apparatus and control method therefor
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
EP1558222A2 (en) * 2002-10-25 2005-08-03 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions containing venlafaxine
US20060246132A1 (en) * 2003-02-07 2006-11-02 Fjalar Johannsson Sustained release formulations of venlafaxine
ATE336988T1 (de) * 2003-07-30 2006-09-15 Pharmathen Sa Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung
US7016014B2 (en) * 2004-02-27 2006-03-21 Asml Netherlands B.V Lithographic apparatus and device manufacturing method

Also Published As

Publication number Publication date
EP1711169A1 (en) 2006-10-18
PL1711169T3 (pl) 2007-10-31
CA2555295C (en) 2011-01-18
US7807195B2 (en) 2010-10-05
ATE361743T1 (de) 2007-06-15
HRP20070353T3 (en) 2008-01-31
EP1711169B1 (en) 2007-05-09
CA2555295A1 (en) 2005-08-18
DE602004006443T2 (de) 2008-01-10
MXPA06008854A (es) 2007-01-23
NZ548504A (en) 2009-03-31
CY1106741T1 (el) 2012-05-23
US20050169985A1 (en) 2005-08-04
HK1091137A1 (en) 2007-01-12
AU2004315136B2 (en) 2010-06-17
NO20063809L (no) 2006-08-25
KR20070000439A (ko) 2007-01-02
UA82597C2 (uk) 2008-04-25
WO2005074895A1 (en) 2005-08-18
PT1711169E (pt) 2007-07-23
ES2287813T3 (es) 2007-12-16
JP2007520547A (ja) 2007-07-26
RU2006129034A (ru) 2008-03-10
AU2004315136A1 (en) 2005-08-18
SI1711169T1 (sl) 2007-10-31
RU2340331C2 (ru) 2008-12-10
IL177243A0 (en) 2006-12-10
DK1711169T3 (da) 2007-09-17
DE602004006443D1 (de) 2007-06-21

Similar Documents

Publication Publication Date Title
BRPI0418283A (pt) formulação de liberação prolongada e processo para a preparação de uma formulação de liberação prolongada
UY32599A (es) Formulación oral sólida de abt-263
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
AR092857A1 (es) Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
BRPI0509184A (pt) composições farmacêuticas
BR112014024964A8 (pt) formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação
BR122019027412B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
ATE442158T1 (de) Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form
BRPI0509971A (pt) uma forma de dosagem farmacêutica, comprimido e método de preparação
BR112015004091A2 (pt) formulação de cápsula de compósito farmacêutico que compreende irbesartan e inibidor de hmg-coa redutase
MXPA06010146A (es) Formas de dosificacion solidas biodisponibles de metaxalona.
BRPI0518789A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
EA201070175A1 (ru) Фармацевтическая композиция контролируемого высвобождения, содержащая толперизона гидрохлорид
MX2009005804A (es) Composicion farmaceutica de memantina.
WO2005107709A3 (en) Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
BRPI0605893A (pt) composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina
BR0302523A (pt) Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.A61K 31/137, A61K 9/20, A61K 9/28, A61K 9/32, A61K 9/36, A61K 9/48, A61P 25/24, A61P 25/00

Ipc: A61K 31/137 (2011.01), A61K 9/20 (2011.01), A61K 9

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A E 11A ANUIDADES.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.